Clinical Trial Update: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial SHR-A1904 vs investigator's choice therapy is recruiting for Claudin18.2-positive second-line advanced or metastatic gastric or gastroesophageal j…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• SHR-A1904

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING